

Pagina 10 | Wat darmintegriteit betekent voor auto-immuunziekten (Marloes van Heijningen)

1. Moudgil KD, Venkatesha SH. *The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation*. Int J Mol Sci. 2022 Dec 21;24(1):95.
2. Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. *The Prevalence of Autoimmune Disorders in Women: A Narrative Review*. Cureus. 2020 May 13;12(5):e8094.
3. Akdis CA. *Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?* Nat Rev Immunol. 2021 Nov;21(11):739–51.
4. Capponi M, Gori A, De Castro G, Ciprandi G, Anania C, Brindisi G, et al. *(R)Evolution in Allergic Rhinitis Add-On Therapy: From Probiotics to Postbiotics and Paraprobiotics*. J Clin Med. 2022 Aug 31;11(17):5154.
5. Kaczynska A, Klosinska M, Chmiel P, Janeczek K, Emeryk A. *The Cross-talk between the Gut Microbiota Composition and the Clinical Course of Allergic Rhinitis: The Use of Probiotics, Prebiotics and Bacterial Lysates in the Treatment of Allergic Rhinitis*. Nutrients. 2022 Oct 16;14(20):4328.
6. Zambrano-Zaragoza JF, Romo-Martínez EJ, Durán-Avelar M de J, García-Magallanes N, Vibanco-Pérez N. *Th17 cells in autoimmune and infectious diseases*. Int J Inflam. 2014;2014:651503.
7. Kim JW, Kwok SK, Choe JY, Park SH. *Recent Advances in Our Understanding of the Link between the Intestinal Microbiota and Systemic Lupus Erythematosus*. Int J Mol Sci. 2019 Sep 30;20(19):4871.
8. Fasano A. *Zonulin, regulation of tight junctions, and autoimmune diseases*. Ann N Y Acad Sci. 2012 Jul;1258(1):25–33.
9. English J, Patrick S, Stewart LD. *The potential role of molecular mimicry by the anaerobic microbiota in the aetiology of autoimmune disease*. Anaerobe. 2023 Mar 20;80:102721.
10. Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. *Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms*. Viruses. 2019 Aug 19;11(8):762.
11. Tajik N, Frech M, Schulz O, Schäfer F, Lucas S, Azizov V, et al. *Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis*. Nat Commun. 2020 Apr 24;11(1):1995.
12. Bae SC, Lee YH. *Association between anti-Porphyromonas gingivalis antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: A meta-analysis*. Z Rheumatol. 2018 Aug;77(6):522–32.
13. Camara-Lemarroy CR, Silva C, Greenfield J, Liu WQ, Metz LM, Yong VW. *Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity*. Mult Scler. 2020 Oct;26(11):1340–50.
14. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigalupi E, et al. *Increased intestinal permeability precedes clinical onset of type 1 diabetes*. Diabetologia. 2006 Dec;49(12):2824–7.

Pagina 18 | Het mestcelactivatiesyndroom, een complexe aandoening (Gonnie van de Lang)

1. MCAS, via www.mcas-hope.de, de Duitse belangenvereniging voor MCAS-patiënten. Geraadpleegd op 17-8-2023.
2. Afrin L. *Mast Cell Activation Disease: Current Concepts*. Lezing conferentie voor de International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis aug. 2021 Via <https://meassociation.org.uk/2021/10/iafcs-me-conference-dr-larry-afrin-on-an-overview-of-mast-cell-activation-disease/>
3. Theoharides, T. C., & Conti, P. (2020). *COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome*. J Biol Regul Homeost Agents, 34(5), 1633-6.
4. Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., ... & Molderings, G. J. (2021). *Diagnosis of mast cell activation syndrome: a global "consensus-2"*. Diagnosis, 8(2), 137-152.
5. Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., ... & Valent, P. (2021). *Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review*. The Journal of Allergy and Clinical Immunology: In Practice, 9(11), 3918-3928.
6. Butterfield, J. H. (2023). *Increased excretion of mast cell mediator metabolites during mast cell activation syndrome*. The Journal of Allergy and Clinical Immunology: In Practice.
7. Carnahan J. *Hidden Infections and Mast Cell Activation Syndrome: What You Need to Know*. Geraadpleegd via <https://www.jillcarnahan.com/2020/12/08/hidden-infections-and-mast-cell-activation-syndrome-what-you-need-to-know>
8. Theoharides, T. C., Valent, P., & Akin, C. (2015). *Mast Cells, Mastocytosis, and Related Disorders*. The New England journal of medicine, 373(2), 163–172.

Pagina 24 | Voedingsintolerantie, een casus (Marieke Lebbink)

1. Rozich JJ, Holmer A, Singh S. *Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases*. Am J Gastroenterol. 2020 Jun;115(6):832-840.
2. Jian L, Anqi H, Gang L, Litian W, Yanyan X, Mengdi W, Tong L. *Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study*. Inflamm Bowel Dis. 2018 Aug 16;24(9):1918-1925.
3. Haskey N, Gold SL, Faith JJ, Raman M. *To Fiber or Not to Fiber: The Swinging Pendulum of Fiber Supplementation in Patients with Inflammatory Bowel Disease*. Nutrients. 2023; 15(5):1080.

Pagina 31 | Rubriek Plant – Artisjok, vriend van de lever (Geert Verhelst)

1. Speroni E, Cervellati R, Govoni P, Guizzardi S, Renzulli C, Guerra MC. *Efficacy of different Cynara scolymus preparations on liver complaints*. J Ethnopharmacol. 2003 Jun;86(2-3):203-11.
2. Ben Salem M, Affes H, Ksouda K, Dhoubi R, Sahnoun Z, Hammami S, Zeghal KM. *Pharmacological Studies of Artichoke Leaf Extract and Their Health Benefits*. Plant Foods Hum Nutr. 2015 Dec;70(4):441-53.
3. Kulza M, Adamska K, Seńczuk-Przybyłowska M, Woźniak A, Wachowiak A, Miechowicz I, Horoszkiewicz M, Nowak G, Florek E. *Karczoch zwyczajny – lek rolinny [Artichoke – herbal drug]*. Przegl Lek. 2012;69(10):1122-6. Polish.
4. Moradi S, Shokri-Mashhadi N, Saraf-Bank S, Mohammadi H, Zobeiri M, Clark CCT, Rouhani MH. *The effects of Cynara scolymus L. supplementation on liver enzymes: A systematic review and meta-analysis*. Int J Clin Pract. 2021 Nov;75(11):e14726. Epub 2021 Aug 23. PMID: 34383355.
5. Amini MR, Sheikhhossein F, Talebyan A, Bazshahi E, Djafari F, Hekmatdoost A. *Effects of Artichoke Supplementation on Liver Enzymes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*. Clin Nutr Res. 2022 Jul 25;11(3):228-239. doi: 10.7762/cnr.2022.11.3.228.
6. Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, Badeli R, Sahebkar A. *Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial*. Phytoter Res. 2018 Jul;32(7):1382-1387. Epub 2018 Mar 9.
7. Kamel AM, Farag MA. *Therapeutic Potential of Artichoke in the Treatment of Fatty Liver: A Systematic Review and Meta-Analysis*. J Med Food. 2022 Oct;25(10):931-942. Epub 2022 Jun 28. PMID: 35763310.
8. Shahinfar H, Bazshahi E, Amini MR, Payandeh N, Pourreza S, Noruzi Z, Shab-Bidar S. *Effects of artichoke leaf extract supplementation or artichoke juice consumption on lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials*. Phytoter Res. 2021 Dec;35(12):6607-6623. Epub 2021 Sep 27.
9. Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, Cicero AFG. *Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis*. Crit Rev Food Sci Nutr. 2018;58(15):2549-2556. Epub 2017 Aug 24.
10. Santos HO, Bueno AA, Mota JF. *The effect of artichoke on lipid profile: A review of possible mechanisms of action*. Pharmacol Res. 2018 Nov;137:170-178. Epub 2018 Oct 9.
11. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammar-skjöld B, Hynes N, Kendrick M, Langsjoen PH, Mascitelli L, McCully KS, Okuyama H, Rosch PJ, Schersten T, Sultan S, Sundberg R. *LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature*. Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-970.
12. Ricieri Mocelin, Matheus Marcon, Glauca D. Santo, Leila Zanatta, Adrieli Sachett, Amanda P. Schönell, Fernanda Bevilacqua, Marta Giachini, Rafael Chitolina, Silvana M. Wildner, Marta M.M.F. Duarte, Greicy M.M. Conterato, Angelo L. Piato, Denise B. Gomes, Walter A. Roman Junior. *Hypolipidemic and antiatherogenic effects of Cynara scolymus in cholesterol-fed rats*. Revista Brasileira de Farmacognosia. Volume 26, Issue 2, 2016, Pages 233-239, ISSN 0102-695X.
13. Sanchez-Lozada LG et al. *Uric Acid and Hypertension: An Update With Recommendations*. Am J Hypertens. 2020 Jul 18;33(7):583-594. Erratum in: Am J Hypertens. 2020 Dec 31;33(12):1150.
14. Moradi M, Sohrabi G, Golbidi M, Yarmohammadi S, Hemati N, Campbell MS, Moradi S, Kermani MAH, Farzaei MH. *Effects of artichoke on blood pressure: A systematic review and meta-analysis*. Complement Ther Med. 2021 Mar;57:102668. Epub 2021 Jan 16.
15. Jalili C, et al *Effects of Cynara scolymus L. on glycemic indices: A systematic review and meta-analysis of randomized clinical trials*. Complement Ther Med. 2020 Aug;52:102496.

Pagina 34 | De rol van antimicrobiële effecten in de darm bij depressie (Dennis Zeilstra)

1. Shanahan F, Ghosh TS, O'Toole PW. *The Healthy Microbiome – What Is the Definition of a Healthy Gut Microbiome?* Gastroenterology. 2021 Jan;160(2):483–94.
2. Tierney BT, Yang Z, Lubber JM, Beaudin M, Wibowo MC, Baek C, et al. *The Landscape of Genetic Content in the Gut and Oral Human Microbiome*. Cell Host Microbe. 2019 Aug 14;26(2):283-295.e8.
3. Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. *Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How?* Microorganisms. 2018 Jul 23;6(3).
4. Kravitz RL, Duan NH, Braslow J. *Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages*. Milbank Q. 2004;82(4):661–87.
5. Kelley JM, Kapchuk TJ. *Group analysis versus individual response: The inferential limits of randomized controlled trials*. Contemp Clin Trials. 2010 Sep;31(5):423–8.
6. Rew L, Harris M, Goldie J. *The ketogenic diet: its impact on human gut microbiota and potential consequent health outcomes: a systematic literature review*. Gastroenterol Hepatol Bed Bench. 2022 Oct 2 [cited 2023 Jun 3];15(4).
7. McBurney MI, Davis C, Fraser CM, Schneeman BO, Huttenhower C, Verbeke K, et al. *Establishing What Constitutes a Healthy Human Gut Microbiome: State of the Science, Regulatory Considerations, and Future Directions*. J Nutr. 2019 Nov 1;149(11):1882–95.

8. Gacesa R, Kurilshikov A, Vich Vila A, Sinha T, Klaassen M a. Y, Bolte LA, et al. *Environmental factors shaping the gut microbiome in a Dutch population*. Nature. 2022 Apr;604(7907):732–9.
 9. Inkpen SA. *Health, ecology and the microbiome*. eLife. 8:e47626.
 10. McDonald JE, Marchesi JR, Koskella B. *Application of ecological and evolutionary theory to microbiome community dynamics across systems*. Proc R Soc B Biol Sci. 2020 Dec 23;287(1941):20202886.
 11. Heintz-Buschart A, Wilmes P. *Human Gut Microbiome: Function Matters*. Trends Microbiol. 2018 Jul;26(7):563–74.
 12. Valles-Colomer M, Blanco-Míguez A, Manghi P, Asnicar F, Dubois L, Golzato D, et al. *The person-to-person transmission landscape of the gut and oral microbiomes*. Nature. 2023 Feb;614(7946):125–35.
 13. Antwis RE, Harrison XA, Cox MJ, editors. *Microbiomes of soils, plants and animals: an integrated approach*. 1st ed. New York, NY: Cambridge University Press; 2020. (Ecological reviews).
 14. Álvarez J, Fernández Real JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz de Pipaon M, et al. *Gut microbes and health*. Gastroenterol Hepatol Engl Ed. 2021 Aug 1;44(7):519–35.
 15. Segura Munoz RR, Mantz S, Martínez I, Li F, Schmaltz RJ, Pudlo NA, et al. *Experimental evaluation of ecological principles to understand and modulate the outcome of bacterial strain competition in gut microbiomes*. ISME J. 2022 Jun;16(6):1594–604.
- Pagina 40 | Zware metalen als dementogenen bij de ziekte van Alzheimer (Frauke Depauw)**
1. Barnes, D.E.; Yaffe, K. *The Projected Effect of Risk Factor Reduction on Alzheimer's Disease Prevalence*. Lancet. Neurol. 2011, 10, 819–828.
 2. Mottet NK, Vahter ME, Charleston JS, and Friberg LT. 1997. *Metabolism of Methylmercury in the Brain and Its Toxicological Significance*. In Metal Ions in Biological Systems, Volume 34: Mercury and Its Effects on Environment and Biology, edited by Sigel A and Sigel H, 371–403.
 3. Dr. Dale Bredensen (2017). *Het Einde Van Alzheimer. Een leefstijl-programma om cognitieve achteruitgang te voorkomen*. ISBN 978 94 6319 172 2.
 4. Mutter, J., Curth, A., Naumann, J., Deth, R. & Walach, H. (2010). *Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism*. Journal of Alzheimer's Disease 22:357-374. d
 5. Madeline M. Foley, Ilana Seidel, Justin Sevier, Julie Wendt, Mikhail Kogan. *One man's swordfish story: The link between Alzheimer's disease and mercury exposure*. Complementary Therapies in Medicine, Volume 52, 2020, 102499. ISSN 0965-2299.
 6. Mutter J, Curth A, Naumann J, Deth R, Walach H. *Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism*. J Alzheimers Dis. 2010;22(2):357-74.
 7. Azar, J., Yousef, M.H., El-Fawal, H.A.N. et al. *Mercury and Alzheimer's disease: a look at the links and evidence*. Metab Brain Dis 36, 361–374 (2021).
 8. Paduraru, E.; Iacob, D.; Rarinca, V.; Rusu, A.; Jijie, R.; Ilie, O.-D.; Ciobica, A.; Nicoara, M.; Doroftei, B. *Comprehensive Review Regarding Mercury Poisoning and Its Complex Involvement in Alzheimer's Disease*. Int. J. Mol. Sci. 2022, 23, 1992.
 9. Tyler CR, Allan AM. *The Effects of Arsenic Exposure on Neurological and Cognitive Dysfunction in Human and Rodent Studies: A Review*. Curr Environ Health Rep. 2014 Mar 21;1(2):132-147.
 10. Anushruti Ashok and others. *Exposure to As-, Cd-, and Pb-Mixture Induces Aβ, Amyloidogenic APP Processing and Cognitive Impairments via Oxidative Stress-Dependent Neuroinflammation in Young Rats* Toxicological Sciences, Volume 143, Issue 1, January 2015, Pages 64–80.
 11. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH. *The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain*. J Neurosci. 2005 Jan 26;25(4):823-9.
 12. Colomina, M.T.; Peris-Sampedro, F. *Aluminum and Alzheimer's Disease*. Adv. Neurobiol. 2017, 18, 183–197.
 13. Virk, S.A.; Eslick, G.D. *Brief Report: Meta-Analysis of Antacid Use and Alzheimer's Disease: Implications for the Aluminum Hypothesis*. Epidemiology 2015, 26, 769–773.
 14. Wang, Z.; Wei, X.; Yang, J.; Suo, J.; Chen, J.; Liu, X.; Zhao, X. *Chronic Exposure to Aluminum and Risk of Alzheimer's Disease: A Meta-Analysis*. Neurosci. Lett. 2016, 610, 200–206.
 15. Exley, C., Clarkson, E. *Aluminium in human brain tissue from donors without neurodegenerative disease: A comparison with Alzheimer's disease, multiple sclerosis and autism*. Sci Rep 10, 7770 (2020).
 16. Bryliński, L.; Kostelecka, K.; Woliński, F.; Duda, P.; Góra, J.; Granat, M.; Flioger, J.; Teresiński, G.; Buszewicz, G.; Sitarz, R.; et al. *Aluminium in the Human Brain: Routes of Penetration, Toxicity, and Resulting Complications*. Int. J. Mol. Sci. 2023, 24, 7228.
 17. Gillette Guyonnet S, Andrieu S, Vellas B. *The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders*. J Nutr Health Aging. 2007 Mar-Apr;11(2):119-24.
 18. Davenward S, Bentham P, Wright J, Crome P, Job D, Polwart A, Exley C. *Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease*. J Alzheimers Dis. 2013;33(2):423-30.
 19. Sophie Gillette-Guyonnet, Sandrine Andrieu, Fatemeh Nourhashemi, Viviane de La Guéronnière, Héléne Grandjean, Bruno Vellas. *Cognitive impairment and composition of drinking water in women: findings of the EPIDOS Study2*. The American Journal of Clinical Nutrition, Volume 81, Issue 4, 2005, Pages 897-902.
 20. Attia H, Albuhaayri S, Alaraidh S, Alotaibi A, Yacoub H, Mohamad R, Al-Amin M. *Biotin, coenzyme Q10, and their combination ameliorate aluminum chloride-induced Alzheimer's disease via attenuating neuroinflammation and improving brain insulin signaling*. J Biochem Mol Toxicol. 2020 May 8:e22519.
 21. Utomo RY, Sugie A, Okada S, Miura K, Nakamura H. *Detoxification of amyloid β fibrils by curcumin derivatives and their verification in a Drosophila Alzheimer's model*. Chem Commun (Camb). 2022 Feb 17;58(15):2576-2579.
 22. Orteca G, Tavanti F, Bednarikova Z, Gazova Z, Rigillo G, Imbriano C, Basile V, Asti M, Rigamonti L, Saladini M, Ferrari E, Menziani MC. *Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases*. Bioorg Med Chem. 2018 Aug 7;26(14):4288-4300.
- Pagina 46 | Rubriek Essentie – Bittere sinaasappel (Geert de Vuyst)**
1. Tan, L., Liao, F. F., Long, L. Z., Ma, X. C., Peng, Y. X., Lu, J. M., Qu, H., & Fu, C. G. (2023). *Essential oils for treating anxiety: a systematic review of randomized controlled trials and network meta analysis*. Frontiers in Public Health, 11, 1144404.
 2. Valussi, M., Donelli, D., Firenzuoli, F., & Antonelli, M. (2021). *Bergamot Oil: Botany, Production, Pharmacology*. Encyclopedia, 1(1), 152–176.
 3. Langrut, D. (2017). *The Citrus Route Revealed: From Southeast Asia into the Mediterranean*. HortScience, 52(6), 814–822.
 4. Velasco, R., & Licciardello, C. (2014). *A genealogy of the citrus family*. Nature Biotechnology, 32(7), 640–642.
 5. Suryawanshi, J. a. S. (2011). *An overview of Citrus aurantium used in treatment of various diseases*. African Journal of Plant Science, 5(7), 390–395.
 6. Sutar, I., Khan, H., Patel, S., Celano, R., & Rastrelli, L. (2018). *An Overview on Citrus aurantium L.: Its Functions as Food Ingredient and Therapeutic Agent*. Oxidative Medicine and Cellular Longevity, 2018, 1–12.
 7. Mannucci, C., Calapai, F., Cardia, L., Inferriera, G., D'Arena, G., Di Pietro, M., Navarra, M., Gangemi, S., Ventura Spagnolo, E., & Calapai, G. (2018). *Clinical Pharmacology of Citrus aurantium and Citrus sinensis for the Treatment of Anxiety*. Evidence-Based Complementary and Alternative Medicine, 2018, 1–18.
 8. Ellena, Jean-Claude, & Paillès, Lionel (2021). *Petit lexique des amateurs épris d'odeurs et de parfums*. Actes Sud.
 9. Bonaccorsi, I., Sciarone, D., Schipilliti, L., Trozzi, A., Fakhry, H. A., & Dugo, G. (2011). *Composition of Egyptian neroli oil*. Natural product communications, 6(7), 1009–1014.
- Pagina 49 | De darm-hersenas als route naar neuroinflammatie (Han Sien)**
1. Cryan et al. (2019). *The Microbiota-Gut-Brain Axis*. Physiological reviews, 99(4), 1877–2013.
 2. Meraz-Rios, M. *Inflammatory process in Alzheimer's Disease*. Frontiers in Integrative Neuroscience. August 2013.
 3. Sommer (2010). CHAPTER 3.11 - Serotonin in Pain and Pain Control. Editor(s): Christian P. Müller, Barry L. Jacobs. Handbook of Behavioral Neuroscience. Elsevier, Vol 21 p457-471. ISBN 9780123746344.
 4. Kądzina-Czaplińska et al. (2019). *How important is tryptophan in human health?* Critical reviews in food science and nutrition, 59(1),72–88.
 5. Crowley, T. et al. *Inhibiting Neuroinflammation: The Role and Therapeutic Potential of GABA in Neuro-Immune Interactions*. Brain, Behavior and Immunity 54 (2016): 260–77.
 6. Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. *Aminobutyric acid production by culturable bacteria from the human intestine*. J Appl Microbiol. 2012 Aug;113(2):411–7.
 7. Bradbury J. *Docosahexaenoic Acid (DHA): An Ancient Nutrient for the Modern Human Brain*. Nutrients. 2011 May; 3(5): 529–554. Published online 2011 May 10. doi: 10.3390/nu3050529.
 8. Bos D, Oranje B et al. *Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder*. Neuropsychopharmacology 40(10), 2298-2306.
 9. Ansari et al. *The Effects of Probiotics and Prebiotics on Mental Disorders: A Review on Depression, Anxiety, Alzheimer, and Autism Spectrum Disorders*. Current pharmaceutical biotechnology, 2020 21(7), 555–565.
 10. Kotzampassi K et al. *Probiotics for infectious diseases: more drugs, less dietary supplementation*. Int J Antimicrob Agents. 2012;40(4):288–96.
 11. Hepburn et al. (2013). *Probiotic supplement consumption alters cytokine production from peripheral blood mononuclear cells: a preliminary study using healthy individuals*. Beneficial Microbes 4(4):313–17
 12. Kelly et al. (2015). *Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders*. Frontiers in cellular neuroscience, 9, 392.
 13. Ait-Belgnaoui, A., Colom, A., Braniste, V., Ramalho, L., Marrot, A., Cartier, C., Houdeau, E., Theodorou, V., & Tompkins, T. (2014). *Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice*. Neurogastroenterology and motility, 26(4), 510–520.
 14. Suzuki (2020). *Regulation of the intestinal barrier by nutrients: The role of tight junctions*. Animal science journal, 91(1), e13357.
 15. Farré et al. (2020). *Intestinal Permeability, Inflammation and the Role of Nutrients*. Nutrients, 12(4), 1185.
 16. Amato, K. et al (2021). *The human gut microbiome and health inequities*. Proceedings of the National Academy of Sciences of the United States of

America, 118(25), e2017947118.

17. European Environment Agency (2020). *Healthy environment, healthy lives: how the environment influences health and well-being in Europe*. EEA Report No 21/2019.
18. Kewalramani, A., Bollinger, M. E., & Postolache, T. T. (2008). *Asthma and Mood Disorders*. *International journal of child health and human development: IJCHD*, 1(2), 115-123.

Pagina 55 | Meervoudige chemische gevoeligheid (Angélique De Beule)

1. Sabrina Rossi, MSc and Alessio Pitidis, MSc. *Multiple Chemical Sensitivity*. *J Occup Environ Med*. 2018 Feb; 60(2): 138-146.
2. Chiara De Luca et al. *The Search for Reliable Biomarkers of Disease in Multiple Chemical Sensitivity and Other Environmental Intolerances*. *Int J Environ Res Public Health*. 2011 Jul; 8(7): 2770-2797.
3. Paolo D. Pigatto et al. *Allergological and Toxicological Aspects in a Multiple Chemical Sensitivity Cohort*. *Oxid Med Cell Longev*. 2013; 2013: 356235.
4. Chiara De Luca et al. *Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes*. *Toxicol Appl Pharmacol*. 2010 Nov 1;248(3):285-92.
5. M. Vadalà et al. *A Proposal for Clinical Biomarkers in Multiple Chemical Sensitivity*. *Clin Ter* 2020; 171 (2):e149-155.
6. Koontz, J. M., Dancy, B. C. R., Horton, C. L., Stallings, J. D., DiVito, V. T., & Lewis, J. A. (2019). *The Role of the Human Microbiome in Chemical Toxicity*. *International journal of toxicology*, 38(4), 251-264.
7. Beniamino Palmieri et al. *The role of sensory and olfactory pathways in multiple chemical sensitivity*. *Reviews on Environmental Health* 2020 Volume 36 Issue 3.
8. Laurie K. Mischley, ND et al. *Safety Survey of Intranasal Glutathione*. *J Altern Complement Med*. 2013 May; 19(5): 459-463.
9. L Galland et al. *Biochemical abnormalities in patients with multiple chemical sensitivities*. *Occup Med*. 1987 Oct-Dec;2(4):713-20.
10. Elena Aguilar-Aguilar et al. *Food Implications in Central Sensitization Syndromes*. *J Clin Med*. 2020 Dec; 9(12): 4106.